KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Gains from Investment Securities (2016 - 2025)

Acadia Pharmaceuticals has reported Gains from Investment Securities over the past 16 years, most recently at $234670.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $234670.0 for Q4 2025, down 98.66% from a year ago — trailing twelve months through Dec 2025 was $234670.0 (down 98.66% YoY), and the annual figure for FY2025 was $234670.0, down 98.66%.
  • Gains from Investment Securities for Q4 2025 was $234670.0 at Acadia Pharmaceuticals, down from $12.5 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for ACAD hit a ceiling of $17.5 million in Q4 2024 and a floor of $234670.0 in Q4 2025.
  • Median Gains from Investment Securities over the past 5 years was $1.6 million (2023), compared with a mean of $7.0 million.
  • Biggest five-year swings in Gains from Investment Securities: skyrocketed 1165.71% in 2024 and later plummeted 98.66% in 2025.
  • Acadia Pharmaceuticals' Gains from Investment Securities stood at $15.1 million in 2021, then rose by 8.31% to $16.3 million in 2022, then increased by 1.75% to $16.6 million in 2023, then grew by 5.37% to $17.5 million in 2024, then plummeted by 98.66% to $234670.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $234670.0 (Q4 2025), $12.5 million (Q3 2025), and $538787.0 (Q2 2025) per Business Quant data.